6th May 2025, New Delhi: Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter ended 31st March, 2025.

Financial Highlights

• Net Sales increased by 17% to Rs.1770 Cr.
• EBITDA up by 9% to Rs. 286 Cr.
• EBITDA Margin at 16% of Sales
• Profit Before Tax up by 5% to Rs.192 Cr.
• Net Profit at Rs.157 Cr.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited, said, “India-Branded Business displayed improved performance, backed by Specialty therapies. While the Animal Health division continued to outperform through a strong portfolio of trusted brands. By deepening our engagement with healthcare professionals and expanding our product pipeline, we have laid a solid foundation for strong, consistent growth, going forward. Our Ex-US business delivered a strong growth of 43% across all markets whereas the US business grew by 20% during the quarter.”

Operational Highlights India Branded Business

• India Branded Business grew by 8% to Rs. 545 Cr. for the quarter.
• Gynaecology, Anti Diabetic, Ophthalmology and Dermatology therapy witnessed healthy growth for the quarter.
• Anti-infective segment and Cough & Cold segment grew by 7% and 11% for the quarter.
• 4 launches during the quarter and 14 launches during the year. New launches continue to do well along with promising future launches across key segments.
• Animal Health business grew by 19% for the quarter. Basket of strong brands continue to drive outperformance.

International Business

• US Generics grew by 20% to Rs. 508 Cr. for the quarter.
• 4 Launches in the US market during the quarter.
• Ex-US International Generics grew by 43% to Rs. 375 Cr. for the quarter.
• 2 ANDA approvals received during the quarter, 220 Cumulative ANDA approvals.

API Business

• API business grew by 4% to Rs. 342 Cr. for the quarter. The summary of Total Revenue is as under: